Last reviewed · How we verify
NCT06690918
Risk Factors Contributing to Oral Cancer in Patients at Dr. Hasan Sadikin General Hospital Bandung
trial in Oral Cavity Cancer in 107 participants. Completed in 4 November 2024.
4 November 2024
Quick facts
| Lead sponsor | Universitas Padjadjaran |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 107 |
| Start date | 1 January 2023 |
| Primary completion | 4 November 2024 |
| Estimated completion | 4 November 2024 |
| Sites | 1 location across Indonesia |
Conditions studied
- Oral Cavity Cancer — all drugs for Oral Cavity Cancer →
Sponsor
Universitas Padjadjaran — full company profile →
Who can join
Eligibility, any sex, with Oral Cavity Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Analytical research with a cross-sectional approach was carried out on patients diagnosed with oral cavity cancer who visited our outpatient clinic in Bandung between 2023 and 2024. Data were collected and analyzed using the chi-square test to determine the significance of the relationship between smoking, alcohol consumption, oral hygiene, and betel quid chewing and oral cavity cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06690918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Cavity Cancer
Currently open trials in the same condition.
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
- NCT05793151 — Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy · NA · recruiting
- NCT05429099 — Mandibular Reconstruction Preplanning (ViPMR) · Phase 2, PHASE3 · recruiting
- NCT05375266 — Immune Biomarker Study for Head and Neck Cancer · recruiting
Other Universitas Padjadjaran trials
Trials by the same sponsor.
- NCT07506486 — Effect of Immersive Virtual Reality Cognitive Rehabilitation on Subacute Stroke Patients (A Pilot Study) · NA · not yet recruiting
- NCT07494357 — Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke · NA · not yet recruiting
- NCT07451899 — TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease · not yet recruiting
- NCT07467954 — Comparative Effectiveness of Long-Pulsed 1064-nm Nd:YAG and Fractional CO₂ Laser in Skin Rejuvenation · NA · recruiting
- NCT07344688 — The Effect of White Tea in Healthy Human Subjects · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06690918 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitas Padjadjaran
- Last refreshed: 15 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06690918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing